165 related articles for article (PubMed ID: 34834934)
1. Clusters of SARS-CoV-2 Lineage B.1.1.7 Infection after Vaccination with Adenovirus-Vectored and Inactivated Vaccines.
de Souza WM; Muraro SP; Souza GF; Amorim MR; Sesti-Costa R; Mofatto LS; Forato J; Barbosa PP; Toledo-Teixeira DA; Bispo-Dos-Santos K; Parise PL; Brunetti NS; Moreira JCO; Costa VA; Cardozo DM; Moretti ML; Barros-Mazon S; Marchesi GF; Ambrosio C; Spilki FR; Almeida VC; Vieira AS; Zambon L; Farias AS; Addas-Carvalho M; Benites BD; Marques RE; Sabino EC; Zuben ABV; Weaver SC; Faria NR; Granja F; Angerami RN; Proença-Módena JL
Viruses; 2021 Oct; 13(11):. PubMed ID: 34834934
[TBL] [Abstract][Full Text] [Related]
2. Investigation of an outbreak of symptomatic SARS-CoV-2 VOC 202012/01-lineage B.1.1.7 infection in healthcare workers, Italy.
Loconsole D; Sallustio A; Accogli M; Leaci A; Sanguedolce A; Parisi A; Chironna M
Clin Microbiol Infect; 2021 Aug; 27(8):1174.e1-1174.e4. PubMed ID: 33984489
[TBL] [Abstract][Full Text] [Related]
3. Recognition of Variants of Concern by Antibodies and T Cells Induced by a SARS-CoV-2 Inactivated Vaccine.
Melo-González F; Soto JA; González LA; Fernández J; Duarte LF; Schultz BM; Gálvez NMS; Pacheco GA; Ríos M; Vázquez Y; Rivera-Pérez D; Moreno-Tapia D; Iturriaga C; Vallejos OP; Berríos-Rojas RV; Hoppe-Elsholz G; Urzúa M; Bruneau N; Fasce RA; Mora J; Grifoni A; Sette A; Weiskopf D; Zeng G; Meng W; González-Aramundiz JV; González PA; Abarca K; Ramírez E; Kalergis AM; Bueno SM
Front Immunol; 2021; 12():747830. PubMed ID: 34858404
[TBL] [Abstract][Full Text] [Related]
4. Effectiveness of adenovirus type 5 vectored and inactivated COVID-19 vaccines against symptomatic COVID-19, COVID-19 pneumonia, and severe COVID-19 caused by the B.1.617.2 (Delta) variant: Evidence from an outbreak in Yunnan, China, 2021.
Ma C; Sun W; Tang T; Jia M; Liu Y; Wan Y; Han J; Rodewald L; Li J; Song Y; Wang Y; Wu D; Wang F; Zheng H; Tang L; Gao GF; Yin Z; An Z
Vaccine; 2022 May; 40(20):2869-2874. PubMed ID: 35400561
[TBL] [Abstract][Full Text] [Related]
5. Dynamic IgG seropositivity after rollout of CoronaVac and BNT162b2 COVID-19 vaccines in Chile: a sentinel surveillance study.
Sauré D; O'Ryan M; Torres JP; Zuniga M; Santelices E; Basso LJ
Lancet Infect Dis; 2022 Jan; 22(1):56-63. PubMed ID: 34509185
[TBL] [Abstract][Full Text] [Related]
6. Neutralisation of SARS-CoV-2 lineage P.1 by antibodies elicited through natural SARS-CoV-2 infection or vaccination with an inactivated SARS-CoV-2 vaccine: an immunological study.
Souza WM; Amorim MR; Sesti-Costa R; Coimbra LD; Brunetti NS; Toledo-Teixeira DA; de Souza GF; Muraro SP; Parise PL; Barbosa PP; Bispo-Dos-Santos K; Mofatto LS; Simeoni CL; Claro IM; Duarte ASS; Coletti TM; Zangirolami AB; Costa-Lima C; Gomes ABSP; Buscaratti LI; Sales FC; Costa VA; Franco LAM; Candido DS; Pybus OG; de Jesus JG; Silva CAM; Ramundo MS; Ferreira GM; Pinho MC; Souza LM; Rocha EC; Andrade PS; Crispim MAE; Maktura GC; Manuli ER; Santos MNN; Camilo CC; Angerami RN; Moretti ML; Spilki FR; Arns CW; Addas-Carvalho M; Benites BD; Vinolo MAR; Mori MAS; Gaburo N; Dye C; Marques-Souza H; Marques RE; Farias AS; Diamond MS; Faria NR; Sabino EC; Granja F; Proença-Módena JL
Lancet Microbe; 2021 Oct; 2(10):e527-e535. PubMed ID: 34258603
[TBL] [Abstract][Full Text] [Related]
7. Postvaccination SARS-COV-2 among Health Care Workers in New Jersey: A Genomic Epidemiological Study.
Mathema B; Chen L; Chow KF; Zhao Y; Zody MC; Mediavilla JR; Cunningham MH; Composto K; Lee A; Oschwald DM; Germer S; Fennessey S; Patel K; Wilson D; Cassell A; Pascual L; Ip A; Corvelo A; Dar S; Kramer Y; Maniatis T; Perlin DS; Kreiswirth BN
Microbiol Spectr; 2021 Dec; 9(3):e0188221. PubMed ID: 34787439
[TBL] [Abstract][Full Text] [Related]
8. Heterologous versus homologous COVID-19 booster vaccination in previous recipients of two doses of CoronaVac COVID-19 vaccine in Brazil (RHH-001): a phase 4, non-inferiority, single blind, randomised study.
Costa Clemens SA; Weckx L; Clemens R; Almeida Mendes AV; Ramos Souza A; Silveira MBV; da Guarda SNF; de Nobrega MM; de Moraes Pinto MI; Gonzalez IGS; Salvador N; Franco MM; de Avila Mendonça RN; Queiroz Oliveira IS; de Freitas Souza BS; Fraga M; Aley P; Bibi S; Cantrell L; Dejnirattisai W; Liu X; Mongkolsapaya J; Supasa P; Screaton GR; Lambe T; Voysey M; Pollard AJ;
Lancet; 2022 Feb; 399(10324):521-529. PubMed ID: 35074136
[TBL] [Abstract][Full Text] [Related]
9. Long-Term Kinetics of SARS-CoV-2 Antibodies and Impact of Inactivated Vaccine on SARS-CoV-2 Antibodies Based on a COVID-19 Patients Cohort.
Zhang S; Xu K; Li C; Zhou L; Kong X; Peng J; Zhu F; Bao C; Jin H; Gao Q; Zhao X; Zhu L
Front Immunol; 2022; 13():829665. PubMed ID: 35154152
[TBL] [Abstract][Full Text] [Related]
10. Antibody responses after a single dose of ChAdOx1 nCoV-19 vaccine in healthcare workers previously infected with SARS-CoV-2.
Havervall S; Marking U; Greilert-Norin N; Ng H; Gordon M; Salomonsson AC; Hellström C; Pin E; Blom K; Mangsbo S; Phillipson M; Klingström J; Hober S; Nilsson P; Åberg M; Thålin C
EBioMedicine; 2021 Aug; 70():103523. PubMed ID: 34391088
[TBL] [Abstract][Full Text] [Related]
11. Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial.
Zhang Y; Zeng G; Pan H; Li C; Hu Y; Chu K; Han W; Chen Z; Tang R; Yin W; Chen X; Hu Y; Liu X; Jiang C; Li J; Yang M; Song Y; Wang X; Gao Q; Zhu F
Lancet Infect Dis; 2021 Feb; 21(2):181-192. PubMed ID: 33217362
[TBL] [Abstract][Full Text] [Related]
12. SARS-CoV-2 Virus-Like Particle Neutralizing Capacity in Blood Donors Depends on Serological Profile and Donor-Declared SARS-CoV-2 Vaccination History.
Drews SJ; Hu Q; Samson R; Abe KT; Rathod B; Colwill K; Gingras AC; Yi QL; O'Brien SF
Microbiol Spectr; 2022 Feb; 10(1):e0226221. PubMed ID: 35171006
[TBL] [Abstract][Full Text] [Related]
13. Characterization of SARS-CoV-2-Specific Humoral and Cellular Immune Responses Induced by Inactivated COVID-19 Vaccines in a Real-World Setting.
Li Z; Xiang T; Liang B; Deng H; Wang H; Feng X; Quan X; Wang X; Li S; Lu S; Yang X; Wang B; Zelinskyy G; Trilling M; Sutter K; Lu M; Dittmer U; Yang D; Zheng X; Liu J
Front Immunol; 2021; 12():802858. PubMed ID: 35003131
[TBL] [Abstract][Full Text] [Related]
14. New infections by SARS-CoV-2 variants of concern after natural infections and post-vaccination in Rio de Janeiro, Brazil.
Goes LR; Siqueira JD; Garrido MM; Alves BM; Pereira ACPM; Cicala C; Arthos J; Viola JPB; Soares MA;
Infect Genet Evol; 2021 Oct; 94():104998. PubMed ID: 34252616
[TBL] [Abstract][Full Text] [Related]
15. Immunogenicity after two doses of inactivated virus vaccine in healthcare workers with and without previous COVID-19 infection: Prospective observational study.
Yalçın TY; Topçu DI; Doğan Ö; Aydın S; Sarı N; Erol Ç; Kuloğlu ZE; Azap ÖK; Can F; Arslan H
J Med Virol; 2022 Jan; 94(1):279-286. PubMed ID: 34468990
[TBL] [Abstract][Full Text] [Related]
16. Prevalence of SARS-CoV-2 Variants of Concern and Variants of Interest in COVID-19 Breakthrough Infections in a Hospital in Monterrey, Mexico.
Galán-Huerta KA; Flores-Treviño S; Salas-Treviño D; Bocanegra-Ibarias P; Rivas-Estilla AM; Pérez-Alba E; Lozano-Sepúlveda SA; Arellanos-Soto D; Camacho-Ortiz A
Viruses; 2022 Jan; 14(1):. PubMed ID: 35062359
[TBL] [Abstract][Full Text] [Related]
17. CoronaVac and ChAdOx1 Vaccination and Gamma Infection Elicited Neutralizing Antibodies against the SARS-CoV-2 Delta Variant.
Fumagalli MJ; Castro-Jorge LA; de Souza WM; de Azevedo PO; Hansen AW; Gazzinelli RT; da Fonseca BAL; Spilki FR; Figueiredo LTM
Viruses; 2022 Feb; 14(2):. PubMed ID: 35215895
[TBL] [Abstract][Full Text] [Related]
18. Anti-SARS-CoV-2 Immunoglobulin Isotypes, and Neutralization Activity Against Viral Variants, According to BNT162b2-Vaccination and Infection History.
Tarkowski M; de Jager W; Schiuma M; Covizzi A; Lai A; Gabrieli A; Corbellino M; Bergna A; Ventura CD; Galli M; Riva A; Antinori S
Front Immunol; 2021; 12():793191. PubMed ID: 34975897
[TBL] [Abstract][Full Text] [Related]
19. Effectiveness of inactivated SARS-CoV-2 vaccines against the Delta variant infection in Guangzhou: a test-negative case-control real-world study.
Li XN; Huang Y; Wang W; Jing QL; Zhang CH; Qin PZ; Guan WJ; Gan L; Li YL; Liu WH; Dong H; Miao YT; Fan SJ; Zhang ZB; Zhang DM; Zhong NS
Emerg Microbes Infect; 2021 Dec; 10(1):1751-1759. PubMed ID: 34396940
[TBL] [Abstract][Full Text] [Related]
20. Impact and effectiveness of mRNA BNT162b2 vaccine against SARS-CoV-2 infections and COVID-19 cases, hospitalisations, and deaths following a nationwide vaccination campaign in Israel: an observational study using national surveillance data.
Haas EJ; Angulo FJ; McLaughlin JM; Anis E; Singer SR; Khan F; Brooks N; Smaja M; Mircus G; Pan K; Southern J; Swerdlow DL; Jodar L; Levy Y; Alroy-Preis S
Lancet; 2021 May; 397(10287):1819-1829. PubMed ID: 33964222
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
